Valuation: PharmaEngine, Inc.

Market Cap 9.47B 293M 257M 239M 219M 412M 28.19B 419M 2.84B 1.11B 13.86B 1.1B 1.08B 47.91B P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 4.79B 148M 130M 121M 111M 209M 14.27B 212M 1.44B 562M 7.02B 556M 544M 24.26B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.82%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-1.35%
1 week+3.45%
Current month+8.03%
1 month+13.82%
3 months+21.14%
6 months-5.72%
Current year-6.39%
1 week 65
Extreme 65
70.5
1 month 58.4
Extreme 58.4
70.5
Current year 53
Extreme 53
74
1 year 53
Extreme 53
81.5
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 16/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 18/01/2018
Director/Board Member - 14/05/2018
Director/Board Member - 12/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+3.45%-15.30%-22.47% 293M
+1.07%-3.49%-3.35%+11.75% 46.86B
+0.25%+1.65%+399.22%+647.65% 40.23B
-0.27%+4.45%+11.81%+60.81% 36.23B
+0.35%+0.87%+4.46%-10.31% 34.72B
+3.14%+1.02%+4.76%+43.00% 27.89B
-0.73%+11.84%+34.39%+134.44% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.10% 13.12B
-2.68%-2.49%-11.36%-34.51% 12.7B
Average +0.07%+1.00%+46.80%+93.27% 24.56B
Weighted average by Cap. +0.48%+0.92%+74.30%+138.01%

Financials

2024 2025
Net sales 2.52B 78M 68.51M 63.71M 58.46M 110M 7.51B 112M 757M 296M 3.69B 293M 287M 12.77B 911M 28.17M 24.74M 23.01M 21.12M 39.68M 2.71B 40.29M 273M 107M 1.33B 106M 103M 4.61B
Net income 1.75B 54.13M 47.54M 44.21M 40.57M 76.23M 5.21B 77.4M 525M 205M 2.56B 203M 199M 8.86B 388M 11.98M 10.52M 9.79M 8.98M 16.88M 1.15B 17.14M 116M 45.41M 567M 44.98M 44.01M 1.96B
Net Debt -3.85B -119M -105M -97.3M -89.29M -168M -11.47B -170M -1.16B -451M -5.64B -447M -438M -19.5B -4.67B -145M -127M -118M -108M -204M -13.92B -207M -1.4B -548M -6.84B -542M -531M -23.65B
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
24/07/26 NT$65.90 -1.35% 538,914
23/07/26 NT$66.80 -2.34% 795,983
22/07/26 NT$68.40 +0.59% 756,301
21/07/26 NT$68.00 +5.75% 2,187,599
20/07/26 NT$64.30 +0.94% 439,119
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock